8 November 2024
Physiomics plc
("Physiomics" or the "Company")
Director Dealing
Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, announces that Dr Peter Sargent, Chief Executive Officer and Director of the Company, has acquired, via market purchases, 459,090 new ordinary shares of 0.4p in the Company ("Ordinary Shares") at a price of 0.66p per Ordinary Share.
Accordingly, Dr Sargent's total holding in the Company will be 459,090 Ordinary Shares, representing approximately 0.2% of the Company's issued share capital and 4,064,175 performance rights under the Company's existing share option schemes (with various vesting targets and expiring on 5 February 2034).
Enquiries:
Physiomics plc
Dr Peter Sargent, CEO
+44 (0)1235 841575
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Limited (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
PDMR Notification Form:
The notification below, which has been made in accordance with the requirements of UK MAR, provides further details.
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Dr Peter Sargent | ||||
| 2. | Reason for the Notification | |||||
| a) | Position/status | Chief Executive Officer and Director | ||||
| b) | Initial notification/amendment | Initial notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Physiomics plc | ||||
| b) | LEI | 213800A71DSZ6ABMTQ91 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted | |||||
| a) | Description of the Financial instrument, type of instrument | Purchase of Ordinary Shares | ||||
| Identification code | GB00BDR6W943 | |||||
| b) | Nature of the Transaction | Purchase of new Ordinary Shares | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information Aggregated volume Price | N/A (Single transaction) | ||||
| e) | Date of the transaction | 7 November 2024 | ||||
| f) | Place of the transaction | London Stock Exchange | ||||
Notes to Editor
About Physiomics
Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
